Orient Bio

Orient Bio Net Tangible Assets

The Net Tangible Assets of Orient Bio (002630.KS) as of Oct 21, 2026 is 68.54 B KRW. In the previous year, Net Tangible Assets was 71.75 B KRW — a change of -4.46% (lower).

Net Tangible Assets

68.54 BKRW

YoY

-4.46%

Last updated:

Net Tangible Assets of Orient Bio is 2026 68.54 B KRW. Net Tangible Assets of Orient Bio was 2025 71.75 B KRW. It decreases by -4.46% lower compared to the previous year.

The Orient Bio Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2019
62.14 B KRW
Jan 1, 2020
49.75 B KRW
Jan 1, 2021
48.07 B KRW
Jan 1, 2022
82.72 B KRW
Jan 1, 2023
71.12 B KRW
Jan 1, 2024
84.98 B KRW
Jan 1, 2025
71.75 B KRW
Jan 1, 2026
68.54 B KRW
The Orient Bio Net Tangible Assets history
YEARNet Tangible AssetsYoY
68.54 BKRW-4.46%
71.75 BKRW-15.57%
84.98 BKRW+19.49%
71.12 BKRW-14.03%
82.72 BKRW+72.08%
48.07 BKRW-3.38%
49.75 BKRW-19.93%
62.14 BKRW+47.58%
42.11 BKRW-25.86%
56.79 BKRW+10.71%
51.30 BKRW+38.57%
37.02 BKRW-11.58%
41.87 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Net Tangible Assets of Orient Bio is 68.54 B KRW in 2026.

Net Tangible Assets of Orient Bio changed from 71.75 B KRW to 68.54 B KRW, representing a -4.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orient Bio

All Key Metrics — Orient Bio